December 14, 2022 from BMJ Journals
‘Chronic neuropathic pain is often debilitating and can have a significant impact on sleep health and quality of life. There is limited information on the impact of cannabinoids on sleep health when treating neuropathic pain. Neuropathic pain affects more than 10% of the global population and it is characterized by dermatomal pain, paresthesia, and sensory gain or deficits that are often debilitating.
The objectives of this systematic review and meta-analysis were to determine the effect of cannabinoids on sleep quality, pain intensity, and patient impression of treatment efficacy in patients with neuropathic pain.
Cannabinoids are useful agents for treating neuropathic pain as evidenced by significant improvement in sleep quality, pain, and PGIC. However, these benefits were noted at the expense of increased daytime somnolence, dizziness, and nausea. With the advent of new agents and more refined cannabis formulations, further research is needed to comprehensively explore treatment effectiveness. Moreover, future work should incorporate clinically validated and objective measures of sleep health to better evaluate this important outcome measure.’
To read the original full study, please click here: